#Janux Therapeutics

Janux Therapeutics Falls 50% After Prostate Cancer Update — Is the Market Overreacting?

Janux Therapeutics stock tumbled 50% after an unexpected prostate cancer study update. Investors and analysts debate whether the sharp sell-off was justified or an overreaction.

Janux Shares Plunge After Prostate Cancer Update; Analyst Calls Move an Overreaction

Janux Therapeutics plunged roughly 50% after a prostate cancer program update; some market observers call the steep sell-off an overreaction, highlighting biotech volatility.